Journal
EUROPEAN CELLS & MATERIALS
Volume 36, Issue -, Pages 218-230Publisher
AO RESEARCH INSTITUTE DAVOS-ARI
DOI: 10.22203/eCM.v036a16
Keywords
Mesenchymal stem cell; secretome; osteoarthritis; animal model; pain; synovial inflammation; cartilage damage
Categories
Funding
- Netherlands Organisation for Scientific Research (Aspasia)
- Applied and Engineering Sciences (AES)
- Austrian Research Promotion Agency (FFG Bridge Grant, Fetocart)
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) represent a promising biological therapeutic option as an osteoarthritis (OA)-modifying treatment. MSCs secrete factors that can counteract inflammatory and catabolic processes and attract endogenous repair cells. The effects of intra-articular injection of MSC secretome on OA-related pain, cartilage damage, subchondral bone alterations and synovial inflammation were studied in a mouse collagenase-induced OA model. The MSC secretome was generated by stimulating human bone-marrowderived MSCs with interferon gamma (IFN gamma) and tumour necrosis factor alpha (TNF alpha). 54 mice were randomly assigned to injections with i) MSC secretome from 20,000 MSCs, ii) 20,000 MSCs or iii) medium (control). Pain was assessed by hind limb weight distribution. Cartilage damage, subchondral bone volume and synovial inflammation were evaluated by histology. MSC-secretome- and MSC-injected mice showed pain reduction at day 7 when compared to control mice. Cartilage damage was more abundant in the control group as compared to healthy knees, a difference which was not found in knees treated with MSC secretome or MSCs. No effects were observed regarding synovial inflammation, subchondral bone volume or the presence of different macrophage subtypes. Injection of MSC secretome, similarly to injection of MSCs, resulted in early pain reduction and had a protective effect on the development of cartilage damage in a murine OA model. By using the regenerative capacities of the MSC-secreted factors, it will be possible to greatly enhance the standardisation, affordability and clinical translatability of the approach. This way, this biological therapy could evolve towards a true disease-modifying anti-osteoarthritic drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available